Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US

References

• Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-32
   Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20
   Google Scholar
• The UK Prospective Diabetes Study Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86
   PubMed Web of Science ®Google Scholar
• Clarke PM, Gray AM, Briggs A, et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-77
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA, US Department of Health and Human Services, 2005.
   Google Scholar
• Kaur J, Singh P, Sowers J. Diabetes and cardiovascular disease. Am J Ther 2002;9:510-5
   PubMedGoogle Scholar
• Jacobs M, Kleisli T, Pio J, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005;70:263-9
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27:S15-35
   PubMedGoogle Scholar
• Mody R, Kalsekar I, Kavookjian J, et al. Economic impact of cardiovascular co-morbidity in patients with type 2 diabetes. J Diabetes Complications 2007;21:75-83
   PubMed Web of Science ®Google Scholar
• Derosa G, Cicero A, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: A twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004;26:744-54
   PubMed Web of Science ®Google Scholar
• Goldberg R, Kendall D, Deeg M, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
   PubMed Web of Science ®Google Scholar
• Palmer A, Roze S, Valentine W, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27-40
   PubMed Web of Science ®Google Scholar
• Palmer A, Roze S, Valentine W, et al. The CORE Diabetes Model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S5-26
   PubMed Web of Science ®Google Scholar
• Tunis SL, Minshall ME. Self-monitoring of blood glucose in type 2 diabetes: cost-effectiveness in the United States. Am J Man Care 2008;14:131-40
   PubMed Web of Science ®Google Scholar
• Minshall ME, Oglesby AK, Wintle ME, et al. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. Value Health 2008;11:22-33
   PubMed Web of Science ®Google Scholar
• Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. J Man Care Pharm 2006;12:726-35
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey (NHANES) Data. Hyattsville, MD: US Department of Health and Human Services, 2000.
   Google Scholar
• Kannel W, Wolf P, Benjamin E, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2-9
   PubMed Web of Science ®Google Scholar
• Phillips S, Whisnant J, O’Fallon W, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clinic Proceedings 1990;65:344-59
   PubMed Web of Science ®Google Scholar
• Miller C, Phillips L, Tate M, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000;23:444-8
   PubMed Web of Science ®Google Scholar
• Harris M. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-8
   PubMed Web of Science ®Google Scholar
• Brandle M, Zhou H, Smith B, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-4
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BEK. Vision disorders in diabetes. In: Harris MI, Cowie CC, Stern MP, et al., eds. Diabetes in America. 2nd edn. Bethesda, MD, USA: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda MD, USA, 1995.
   Google Scholar
• Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arc Intern Med 1992;152:610-6
   PubMed Web of Science ®Google Scholar
• Massing M, Foley K, Sueta C, et al. Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes Care. 2003;26:991-7
   PubMed Web of Science ®Google Scholar
• McFarlane S, Jacober S, Winer N, et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-23
   PubMed Web of Science ®Google Scholar
• O’Brien J, Patrick A, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-38
   PubMed Web of Science ®Google Scholar
• US Department of Labor, Bureau of Labor Statistics, Consumer price index for the healthcare sector, 2006.
   Google Scholar
• St. Anthony's DRG Guidebook. A comprehensive resource to the DRG classification system, Reston, VA, USA. Medicode, 2001.
   Google Scholar
• Shearer A, Scuffham P, Gordois A, et al. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:2305-10
   PubMed Web of Science ®Google Scholar
• Bullano M, Al-Zakwani I, Fisher M, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-8
   PubMed Web of Science ®Google Scholar
• Drug Topics Redbook. Medical Economics Company, ed. Montvale, NJ, USA. Thomson PDR, 2004.
   Google Scholar
• Golan L, Birkmeyer J, Welch H. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-7
   PubMed Web of Science ®Google Scholar
• O’Brien J, Shomphe L, Kavanagh P. Direct medical costs of complications from type 2 diabetes in the US. Diabetes Care 1998;21:296-308
   PubMedGoogle Scholar
• Kantor J, Margolis D. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg 2001;27:347-51
   PubMed Web of Science ®Google Scholar
• Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Dec Making 2002;22:340-9
   PubMed Web of Science ®Google Scholar
• Tengs T, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38:583-637
   PubMed Web of Science ®Google Scholar
• Begg S, Vos T, Barker B, et al. The burden of disease and injury in Australia 2003. Australian Institute of Health and Welfare, 2007. Available from http://www.aihw.gov.au/bod/index.cfm [Last accessed 7 July 2007].
   Google Scholar
• Carrington A, Mawdsley S, Morley M. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 1996;32:19-25
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence (NICE). Technology appraisal guidance on the use of long-acting insulin analogues, No. 53, December, 2002. Available from http://www.nice.org.uk/guidance/[Last accessed 15 May 2007].
   Google Scholar
• American Diabetes Association.Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-5
   PubMed Web of Science ®Google Scholar
• Tarn T, Smith M. Pharmacoeconomics guidelines around the world. ISPOR Connections 2004;10:5-15
   Google Scholar
• Palmer AJ, Roze S, Valentine W, et al. Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model. Curr Med Res Opin 2004;20:53-8
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci 2001;101:671-9
   PubMed Web of Science ®Google Scholar
• Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81
   PubMed Web of Science ®Google Scholar
• Stratton IM, Kohner EM, Aldington SJ, et al. UKPDS 50: risk factors for incidence and progression of retinopathy in type II diabetes over 6 years from diagnosis. Diabetologia 2001;44:156-63
   PubMed Web of Science ®Google Scholar
• Halpern E, Weinstein M, Hunink M, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Dec Making 2000;20:314-22
   PubMed Web of Science ®Google Scholar
• Nissen S, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
   PubMed Web of Science ®Google Scholar
• Coyle D, Palmer A, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002;20:31-42
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Wheeler DC. Cardiovascular and survival paradoxes in dialysis patients: misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Seminars in Dialysis 2007;20:498-503
   PubMed Web of Science ®Google Scholar
• Tilden DP, Mariz S, O’Bryan-Tear G, et al. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007;25:39-54
   PubMed Web of Science ®Google Scholar